The cancer-specific protein SSX-2 induces the immune system to attack malignant cells in people with melanoma skin cancer.The finding offers scientists a new target for development of therapeutic melanoma vaccine, says a study published in the April 15 issue of the Journal of Clinical Investigation.The discovery was made by scientists from the Cancer Vaccine Collaborative (CVC), a partnership between the Cancer Research Institute and the Ludwig Institute for Cancer Research at Memorial Sloan-Kettering Cancer Center in New York City.
